Novartis, Takeda See Industry Better Prepared For Next Pandemic
Repurposing Drugs Not Ideal
Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.
You may also be interested in...
Novartis counters speculation around pandemic-related staff cutbacks in India, saying that it actually upped the number of hires across its operations since January 2020. A senior executive separately provides a buoyant outlook for the Swiss firm’s global services operations in Hyderabad, which has added a significant number of new roles.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.